Treatment of the antiphospholipid antibody syndrome: Progress in the last five years?
- Cite this article as:
- Petri, M. Curr Rheumatol Rep (2000) 2: 256. doi:10.1007/s11926-000-0088-5
- 29 Downloads
The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains highintensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful “proving ground” of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.